Lumicitabine
- Generic Name
- Lumicitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25ClFN3O6
- CAS Number
- 1445385-02-3
- Unique Ingredient Identifier
- BNW5PQ52G1
- Background
Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).
- Associated Conditions
- -
- Associated Therapies
- -
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals
DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath